Sumatriptan Nasal Spray for Acute Migraine
DOI:
https://doi.org/10.15844/pedneurbriefs-14-11-3Keywords:
Higher Efficacy Rates, Photophobia, Headache RecurrenceAbstract
A multicenter, randomized, double-blind, placebo-controlled trial of sumatriptan nasal spray (5 mg, 10 mg, and 20 mg) was conducted in 653 adolescents presenting with acute migraine at the Palm Beach Headache Center, Florida; Cleveland Clinic, OH; Michigan Headache Institute, Ann Arbor; and San Antonio Center, TX.Published
2000-11-01
Issue
Section
Headache Disorders
License
Copyright (c) 2000 The Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Pediatric Neurology Briefs is owned and published by Pediatric Neurology Briefs Publishers © 1987-2018. While the information is believed to be true and accurate at publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any error or omissions. The publisher makes no warranty, express or implied, with respect to the material contained herein.